A clinical study of TG6002 and flucytosine in patients with gastro-intestinal tumors
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Primary objectives: Phase I: determination of the recommended phase II dose Phase IIa: efficacy of multiple administrations of TG6002 in combination with flucytosine (or Ancotil or 5-FC) Primary endpoints: Phase I: adverse events, serious adverse events, change in standard laboratory parameters and vital signs, dose-limiting toxicities. Phase IIa: overall response rate.
创建时间：
2018-07-15
